Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of SAGE-217 in the Treatment of Subjects With Essential Tremor

NCT02978781 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02978781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02978781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of SAGE-217 in the Treatment of Subjects With Essential Tremor
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
March 24, 2017
Completion date
December 5, 2017
Enrollment
34 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

essential tremor